Yoshida Midori, Katsuda Shin-Ichi, Maekawa Akihiko
Division of Pathology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
J Toxicol Pathol. 2012 Dec;25(4):241-7. doi: 10.1293/tox.25.241. Epub 2012 Dec 20.
Involvements of estrogen receptor (ER)α, proliferating cell nuclear antigen (PCNA) and p53 in the uterine carcinogenesis process in Donryu rats, a high yield strain of the uterine cancer were investigated immunohistochemically. ERα was expressed in atypical endometrial hyperplasia, accepted as a precancerous lesion of the uterine tumors, as well as well- and in moderately-differentiated endometrial adenocarcinomas, and the intensities of expression were similar to those in the luminal epithelial cells of the atrophic uterus at 15 months of age. The expression, however, was negative in the tumor cells of poorly differentiated type. Good growth of implanted grafts of the poorly-differentiated adenocarcinomas in both sexes with or without gonadectomy supported the estrogen independency of tumor progression to malignancy. PCNA labeling indices were increased with tumor development from atypical hyperplasia to adenocarcinoma. The tumor cells in poorly-differentiated adenocarcinomas were positive for p53 positive but negative for p21 expression, suggesting accumulation of mutated p53. These results indicate that the consistent ERα expression is involved in initiation and promotion steps of uterine carcinogenesis, but not progression. In addition, PCNA is related to tumor development and the expression of mutated p53 might be a late event during endometrial carcinogenesis.
采用免疫组织化学方法,对子宫癌高发病率品系——东乡大鼠子宫致癌过程中雌激素受体(ER)α、增殖细胞核抗原(PCNA)和p53的参与情况进行了研究。ERα在非典型子宫内膜增生(被认为是子宫肿瘤的癌前病变)以及高分化和中分化子宫内膜腺癌中均有表达,其表达强度与15月龄萎缩子宫的腔上皮细胞中的表达强度相似。然而,在低分化型肿瘤细胞中,ERα表达呈阴性。无论有无性腺切除,低分化腺癌在雌雄两性中植入移植物的良好生长均支持肿瘤进展为恶性肿瘤与雌激素无关。随着肿瘤从非典型增生发展到腺癌,PCNA标记指数增加。低分化腺癌中的肿瘤细胞p53呈阳性,但p < sub > 21 < / sub >表达呈阴性,提示存在突变型p53的积累。这些结果表明,持续的ERα表达参与子宫致癌作用的起始和促进步骤,但不参与进展过程。此外,PCNA与肿瘤发展相关,突变型p53的表达可能是子宫内膜致癌过程中的晚期事件。